Last reviewed · How we verify

NCT07016555

Burning Mouth Syndrome: Symptoms and Management

Recruiting now EARLY_PHASE1 Last updated 11 June 2025
What this trial tests

EARLY_PHASE1 trial testing Oral cooling spray in Burning Mouth Syndrome in 50 participants. Currently enrolling.

Timeline
11 June 2025
Primary endpoint
31 August 2025
15 December 2025

Quick facts

Lead sponsorUniversity of Massachusetts, Amherst
PhaseEARLY_PHASE1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment50
Start date11 June 2025
Primary completion31 August 2025
Estimated completion15 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Massachusetts, Amherst

Who can join

18 and older, any sex, with Burning Mouth Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study aims to evaluate how an oral cooling spray, currently a commercial dietary supplement, impacts symptoms associated with burning mouth syndrome (BMS). This study will examine symptoms, frequency, and severity, along with other related side effects of BMS on food intake, enjoyment, and quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Burning Mouth Syndrome

Currently open trials in the same condition.

Other University of Massachusetts, Amherst trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07016555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing